Compare Amphastar Pharmaceuticals Inc (AMPH) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Stanley Black & Decker, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Stanley Black & Decker, Inc. trades at $88.22 (market cap $13.71B). The key difference: Stanley Black & Decker, Inc. is far larger — about 16.6× Amphastar Pharmaceuticals Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.76% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SWK | |
|---|---|---|
Market Cap | $826.08M | $13.71B |
Sector | Health | — |
52-Week High | $30.81 | $94.12 |
52-Week Low | $16.87 | $62.12 |
Enterprise Value | $1.22B | $19.88B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Stanley Black & Decker (SWK) trades at $88.22, up 1.61% with a bullish technical signal and consistent earnings beats. The stock shows strong valuation metrics with P/S of 0.88 and P/B of 1.53, while profitability remains modest with 2.44% net margin. Recent corporate actions include a $0.83 dividend payment, and cash flow trends indicate operational stability despite slight net outflows.
SWK presents a mixed outlook with positive earnings momentum and aerospace/automotive demand offset by Tools & Outdoor segment weakness and elevated debt. Analyst consensus leans neutral (51% Hold) with $82.75 price target below current levels. Key risks include consumer sentiment pressures and high debt load, though cost-saving initiatives support turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
